| Literature DB >> 31259300 |
Nils Skajaa1, Erzsébet Horváth-Puhó1, Kasper Adelborg1,2, Paolo Prandoni3, Kenneth J Rothman4,5, Henrik Toft Sørensen1.
Abstract
Background Many cardiovascular conditions exhibit seasonality in occurrence and mortality, but little is known about the seasonality of venous thromboembolism. Methods Using Danish registries, we identified all patients with deep vein thrombosis, pulmonary embolism, splanchnic vein thrombosis, cerebral vein thrombosis, and retinal vein thrombosis during 1977-2016. We tallied monthly deaths occurring within 90 days of the venous thromboembolism diagnosis. We estimated peak-to-trough ratios and timing of the peak of both diagnoses and deaths summed over all years of the study period. The departure from 1.0 of the peak-to-trough ratio measures the intensity of any seasonal pattern. Results We estimated a peak-to-trough ratio of 1.09 (95% confidence interval: 1.07-1.11) for deep vein thrombosis and 1.22 (1.19-1.24) for pulmonary embolism occurrence. The peak-to-trough ratios for splanchnic vein thrombosis, cerebral vein thrombosis, and retinal vein thrombosis occurrence were 1.10 (1.01-1.20), 1.19 (1.00-1.40), and 1.12 (1.07-1.17), respectively. The occurrence of all conditions peaked during winter or fall. In time trend analyses, the peak-to-trough ratio increased considerably for splanchnic vein thrombosis, cerebral vein thrombosis, and retinal vein thrombosis occurrence. In associated mortality, the peak-to-trough ratio for deep vein thrombosis was larger (1.15, 1.07-1.23) than that for pulmonary embolism (1.04, 1.01-1.08). Discussion Excess winter risks were modest, but more marked for pulmonary embolism occurrence than for deep vein thrombosis occurrence. The seasonal pattern intensified throughout the study period for splanchnic vein thrombosis, cerebral vein thrombosis, and retinal vein thrombosis. The winter peak in mortality following pulmonary embolism was smaller than that for deep vein thrombosis.Entities:
Keywords: epidemiology; peak-to-trough ratio; seasonality; venous thromboembolism
Year: 2019 PMID: 31259300 PMCID: PMC6598086 DOI: 10.1055/s-0039-1692399
Source DB: PubMed Journal: TH Open ISSN: 2512-9465
Characteristics (no., %) of patients with deep vein thrombosis, pulmonary embolism, provoked VTE, unprovoked VTE, and splanchnic vein thrombosis during 1977–2016, and cerebral vein thrombosis and retinal vein thrombosis during 1994–2016
| Deep venous thrombosis | Pulmonary embolism | Provoked VTE | Unprovoked VTE | Splanchnic venous thrombosis | Cerebral venous thrombosis | Retinal venous thrombosis | |
|---|---|---|---|---|---|---|---|
| All patients | 101,895 | 84,080 | 69,908 | 116,067 | 3,972 | 1,118 | 15,706 |
| Women | 52,517 (51.5) | 44,853 (53.3) | 38,411 (54.9) | 58,959 (50.8) | 1,919 (48.3) | 679 (61.0) | 7,973 (50.8) |
| Median age (25th–75th percentiles), y | 65 (51–76) | 71 (60–79) | 70 (59–79) | 68 (52–77) | 66 (53–77) | 45 (27–62) | 71 (62–79) |
| Age groups, y | |||||||
| 0–29 | 5,228 (5.1) | 2,419 (2.9) | 2,175 (3.1) | 5,472 (4.7) | 195 (4.9) | 334 (29.9) | 114 (0.7) |
| 30–49 | 18,862 (18.5) | 8,874 (10.6) | 7,836 (11.2) | 19,900 (17.1) | 617 (15.5) | 309 (27.6) | 1,125 (7.2) |
| 50–69 | 37,518 (36.8) | 27,969 (33.3) | 24,524 (35.1) | 40,963 (35.3) | 1,566 (39.4) | 309 (27.6) | 5,992 (38.2) |
| 70+ | 40,287 (39.5) | 44,818 (53.3) | 35,373 (50.6) | 49,732 (42.8) | 1,594 (40.1) | 166 (14.8) | 8,475 (54.0) |
| Charlson Comorbidity Index score | |||||||
| 0 | 59,949 (58.8) | 42,300 (50.3) | 24,021 (34.4) | 78,228 (67.4) | 1,568 (39.5) | 701 (62.7) | 8,752 (55.7) |
| 1 | 16,022 (15.7) | 14,397 (17.1) | 8,685 (12.4) | 21,734 (18.7) | 733 (18.5) | 216 (19.3) | 2,867 (18.3) |
| 2 | 13,325 (13.1) | 13,070 (15.5) | 17,254 (24.7) | 9,141 (7.9) | 582 (14.7) | 104 (9.3) | 2,096 (13.3) |
| 3+ | 12,599 (12.4) | 14,313 (17.0) | 19,948 (28.5) | 6,964 (6.0) | 1,089 (27.4) | 97 (8.7) | 1,991 (12.7) |
| Calendar period | |||||||
| 1977–1993 | 29,103 (28.6) | 31,284 (37.2) | 24,347 (34.8) | 36,040 (31.1) | 1,374 (34.6) | NA | NA |
| 1994–2008 | 43,725 (42.9) | 25,400 (30.2) | 23,070 (33.0) | 46,055 (39.7) | 1,062 (26.7) | 581 (52.0) | 8,181 (52.1) |
| 2009–2016 | 29,067 (28.5) | 27,396 (32.6) | 22,491 (32.2) | 33,972 (29.3) | 1,536 (38.7) | 537 (48.0) | 7,525 (47.9) |
| Type of diagnosis | |||||||
| Primary | 79,529 (78.0) | 56,353 (67.0) | 45,504 (65.1) | 90,378 (77.9) | 2,320 (58.4) | 886 (79.2) | 12,385 (78.9) |
| Secondary | 22,366 (22.0) | 27,727 (33.0) | 24,404 (34.9) | 25,689 (22.1) | 1,652 (41.6) | 232 (20.8) | 3,321 (21.1) |
| Department | |||||||
| Inpatient | 86,920 (85.3) | 79,370 (94.4) | 63,691 (91.1) | 102,599 (88.4) | 3,551 (89.4) | 976 (87.3) | 590 (3.8) |
| Outpatient | 14,975 (14.7) | 4,710 (5.6) | 6,217 (8.9) | 13,468 (11.6) | 421 (10.6) | 142 (12.7) | 15,116 (96.2) |
Abbreviation: VTE, venous thromboembolism (deep venous thrombosis and pulmonary embolism).
Fig. 1Summarized cases within each calendar month during 1977–2016 (occurrence of deep vein thrombosis, pulmonary embolism, provoked venous thromboembolism, unprovoked venous thromboembolism, splanchnic vein thrombosis) and 1994–2016 (occurrence of cerebral vein thrombosis and retinal vein thrombosis), adjusted for the length of month with a fitted sine curve and 95% confidence band.
Peak-to-trough ratios (95% confidence intervals) of summarized monthly cases during 1977–2016 (deep vein thrombosis, pulmonary embolism, provoked VTE, unprovoked VTE, and splanchnic vein thrombosis) and during 1994–2016 (cerebral vein thrombosis and retinal vein thrombosis)
| Deep venous thrombosis | Pulmonary embolism | Provoked VTE | Unprovoked VTE | Splanchnic venous thrombosis | Cerebral venous thrombosis | Retinal venous thrombosis | |
|---|---|---|---|---|---|---|---|
| All patients | 1.09 (1.07–1.11) | 1.22 (1.19–1.24) | 1.15 (1.13–1.18) | 1.13 (1.11–1.15) | 1.10 (1.01–1.20) | 1.19 (1.00–1.40) | 1.12 (1.07–1.17) |
| Women | 1.06 (1.03–1.09) | 1.23 (1.20–1.27) | 1.15 (1.11–1.18) | 1.11 (1.08–1.14) | 1.30 (1.10–1.53) | 1.11 (1.00–1.38) | 1.08 (1.01–1.15) |
| Men | 1.13 (1.10–1.16) | 1.20 (1.17–1.23) | 1.16 (1.12–1.19) | 1.16 (1.13–1.19) | 1.17 (1.00–1.35) | 1.12 (1.00–1.47) | 1.15 (1.08–1.23) |
| Age groups, y | |||||||
| 0–29 | 1.05 (1.00–1.14) | 1.25 (1.11–1.40) | 1.08 (1.00–1.22) | 1.11 (1.03–1.19) | 1.09 (1.00–1.75) | 1.23 (1.00–1.67) | 1.06 (1.00–1.78) |
| 30–49 | 1.05 (1.01–1.10) | 1.06 (1.00–1.13) | 1.09 (1.02–1.16) | 1.08 (1.04–1.12) | 1.24 (1.00–1.60) | 1.09 (1.00–1.50) | 1.20 (1.01–1.42) |
| 50–69 | 1.10 (1.07–1.13) | 1.23 (1.19–1.27) | 1.16 (1.12–1.21) | 1.14 (1.11–1.18) | 1.30 (1.09–1.54) | 1.10 (1.00–1.52) | 1.12 (1.04–1.20) |
| 70+ | 1.17 (1.13–1.20) | 1.25 (1.22–1.29) | 1.17 (1.13–1.20) | 1.23 (1.20–1.26) | 1.04 (1.00–1.26) | 1.11 (1.00–1.71) | 1.10 (1.03–1.17) |
| Charlson Comorbidity Index score | |||||||
| 0 | 1.13 (1.11–1.16) | 1.25 (1.21–1.28) | 1.22 (1.18–1.27) | 1.16 (1.14–1.18) | 1.10 (1.00–1.32) | 1.16 (1.00–1.44) | 1.09 (1.03–1.16) |
| 1 | 1.08 (1.03–1.13) | 1.20 (1.14–1.26) | 1.11 (1.04–1.18) | 1.11 (1.07–1.15) | 1.27 (1.00–1.67) | 1.19 (1.00–1.74) | 1.16 (1.05–1.29) |
| 2 | 1.03 (1.00–1.08) | 1.17 (1.11–1.23) | 1.12 (1.08–1.17) | 1.05 (1.00–1.12) | 1.01 (1.00–1.34) | 1.07 (1.00–1.85) | 1.07 (1.00–1.21) |
| 3+ | 1.01 (1.00–1.06) | 1.19 (1.14–1.25) | 1.11 (1.06–1.15) | 1.06 (1.00–1.14) | 1.34 (1.01–1.63) | 1.03 (1.00–1.82) | 1.17 (1.03–1.33) |
| Calendar period | |||||||
| 1977–1993 | 1.17 (1.13–1.21) | 1.23 (1.20–1.28) | 1.18 (1.14–1.22) | 1.22 (1.18–1.26) | 1.04 (1.00–1.21) | NA | NA |
| 1994–2008 | 1.07 (1.04–1.11) | 1.19 (1.15–1.24) | 1.13 (1.09–1.17) | 1.10 (1.07–1.13) | 1.15 (1.00–1.37) | 1.08 (1.00–1.36) | 1.07 (1.01–1.14) |
| 2009–2016 | 1.04 (1.01–1.08) | 1.22 (1.18–1.26) | 1.14 (1.10–1.18) | 1.09 (1.05–1.12) | 1.20 (1.04–1.39) | 1.29 (1.01–1.65) | 1.16 (1.08–1.23) |
| Type of diagnosis | |||||||
| Primary | 1.09 (1.07–1.11) | 1.22 (1.20–1.25) | 1.15 (1.12–1.18) | 1.13 (1.11–1.15) | 1.12 (1.00–1.26) | 1.10 (1.00–1.32) | 1.11 (1.06–1.17) |
| Secondary | 1.10 (1.06–1.15) | 1.20 (1.16–1.24) | 1.15 (1.11–1.19) | 1.15 (1.11–1.19) | 1.03 (1.00–1.18) | 1.09 (1.00–1.57) | 1.12 (1.02–1.24) |
| Department | |||||||
| Inpatient | 1.10 (1.08–1.12) | 1.22 (1.19–1.24) | 1.15 (1.13–1.18) | 1.14 (1.12–1.26) | 1.04 (1.00–1.15) | 1.20 (1.00–1.43) | 1.05 (1.00–1.33) |
| Outpatient | 1.08 (1.03–1.13) | 1.23 (1.13–1.33) | 1.18 (1.10–1.27) | 1.09 (1.04–1.15) | 1.23 (1.00–1.62) | 1.06 (1.00–1.70) | 1.11 (1.06–1.16) |
|
Plasmode simulation
| 1.05 (1.03–1.07) | 1.09 (1.07–1.11) | 1.06 (1.04–1.09) | 1.06 (1.05–1.09) | 1.05 (1.00–1.14) | 1.13 (1.00–1.31) | 1.07 (1.03–1.12) |
Abbreviations: NA, not applicable; VTE, venous thromboembolism (deep venous thrombosis and pulmonary embolism).
Mean peak-to-trough ratio from random reassignment of monthly cases 1000 times.
Fig. 2Summarized deaths within each calendar month during 1977–2016 (within 90 days following deep vein thrombosis, pulmonary embolism, provoked venous thromboembolism, unprovoked venous thromboembolism, and splanchnic vein thrombosis) and 1994–2016 (within 90 days following cerebral vein thrombosis and retinal vein thrombosis), adjusted for the length of month with a fitted sine curve and 95% confidence band.
Peak-to-trough ratios (95% confidence intervals) of summarized monthly deaths during 1977–2016 (within 90 days following deep vein thrombosis, pulmonary embolism, provoked VTE, unprovoked VTE, and splanchnic vein thrombosis) and during 1994–2016 (within 90 days following cerebral vein thrombosis and retinal vein thrombosis)
| Deep venous thrombosis | Pulmonary embolism | Provoked VTE | Unprovoked VTE | Splanchnic venous thrombosis | Cerebral venous thrombosis | Retinal venous thrombosis | |
|---|---|---|---|---|---|---|---|
| All patients | 1.15 (1.07–1.23) | 1.04 (1.01–1.08) | 1.05 (1.01–1.09) | 1.22 (1.17–1.28) | 1.08 (1.00–1.24) | 1.31 (1.00–2.52) | 1.05 (1.00–1.74) |
|
Plasmode simulation
| 1.06 (1.00–1.13) | 1.04 (1.01–1.08) | 1.03 (1.00–1.07) | 1.10 (1.06–1.14) | 1.09 (1.00–1.23) | 1.14 (1.00–2.01) | 1.04 (1.00–1.68) |
Abbreviation: VTE, venous thromboembolism (deep venous thrombosis and pulmonary embolism).
Mean peak-to-trough ratio from random reassignment of monthly deaths 1,000 times.